News from IAS 2017

The 9th IAS Conference on HIV Science (IAS 2017) is taking place in Paris, France, in July.

We will be reporting on key research presented at the conference, publishing news online and sending out news summary bulletins by email.

“The coverage made me feel I was at the conference and I appreciate NAM's effort in sharing the bulletins.” NAM bulletin subscriber

aidsmap news from IAS 2017

Experts concur that event-related oral PrEP probably won’t work for women

Two presentations at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug

Published
01 September 2017
By
Gus Cairns
Who are trans women acquiring HIV from?

There is a lot we don’t know about trans women’s HIV risk, why they are so vulnerable to HIV and who trans women are acquiring HIV

Published
29 August 2017
By
Gus Cairns
One in seven people offered PrEP in African study start it immediately

One in seven people (14%) offered pre-exposure prophylaxis (PrEP) in a large community study of enhanced HIV testing and treatment in Kenya and Uganda started

Published
28 August 2017
By
Gus Cairns
Trans women wary of antiretroviral drug and hormone interactions

Transgender women living with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminising hormones,

Published
23 August 2017
By
Liz Highleyman
People with HIV are at risk for liver fibrosis and steatosis

Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with

Published
21 August 2017
By
Liz Highleyman
Peripheral artery disease more common in people with HIV with lower CD4 counts

Peripheral artery disease, one of the most common forms of cardiovascular disease, occurs more frequently in people with HIV who have CD4 cell counts below

Published
15 August 2017
By
Keith Alcorn
PrEP use in US exceeds 100,000 in Gilead pharmacy survey

An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of

Published
14 August 2017
By
Liz Highleyman
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir was associated with lipid reductions in people with HIV at higher risk of heart

Published
09 August 2017
By
Keith Alcorn
Boosted darunavir plus lamivudine matches three-drug regimen

A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results of the ANDES study presented

Published
08 August 2017
By
Keith Alcorn
Why curing HIV may be like curing cancer – and may be as difficult

For the last few years, a specialist symposium on HIV cure research has preceded the International AIDS Society (IAS) Conferences and this one was no exception,

Published
03 August 2017
By
Gus Cairns
← First12345Next →

Email bulletins

Sign up for our conference bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Tweets from IAS 2017

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.